Related Experiment Video

Updated: Jul 16, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study

M Sandberg-Wollheim1, C Bever, J Carter

  • 1Department of Neurology, University Hospital, 221 85 Lund, Sweden. Magnhild.Sandberg@neurol.lu.se

Journal of Neurology
|January 18, 2005
PubMed

Insights

The EVIDENCE study found that 44 mcg of interferon beta-1a subcutaneously three times weekly showed better clinical outcomes for relapsing-remitting multiple sclerosis (RRMS) than 30 mcg intramuscularly weekly, despite more mild adverse events.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
  • Interferon (IFN) beta-1a is a disease-modifying therapy used in RRMS treatment.
  • Optimizing IFN beta-1a dosing regimens is crucial for balancing efficacy and safety.

Purpose of the Study:

  • To directly compare the efficacy and safety of two distinct interferon (IFN) beta-1a dosing regimens in RRMS patients.
  • To evaluate the risk-benefit ratio of 30 mcg intramuscularly once weekly versus 44 mcg subcutaneously three times weekly over 64 weeks.

Main Methods:

  • The EVIDENCE study was a direct comparative trial involving 338 patients on 30 mcg IFN beta-1a intramuscularly weekly and 339 patients on 44 mcg IFN beta-1a subcutaneously three times weekly.
  • Patients were monitored for an average of 64 weeks with clinical assessments and safety blood tests at regular intervals.
  • Adverse events, including injection-site reactions, hepatic, and haematological events, were systematically recorded and analyzed.

Main Results:

  • Overall adverse events were more frequent with the 44 mcg subcutaneous three times weekly regimen, primarily due to mild injection-site reactions.
  • Hepatic and haematological adverse events were also more common with the 44 mcg tiw regimen, but severe events did not differ between groups.
  • Flu-like symptoms were more frequent and severe with the 30 mcg intramuscularly weekly regimen, with comparable serious adverse events and discontinuations for both groups.

Conclusions:

  • The 44 mcg subcutaneous three times weekly regimen of IFN beta-1a demonstrated superior clinical and MRI outcomes in RRMS patients over 64 weeks.
  • Despite a higher incidence of mild adverse events, the 44 mcg tiw regimen did not negatively impact treatment adherence.
  • The risk-benefit profile favors the 44 mcg tiw regimen for interferon therapy in RRMS during the study period.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...